SUTRO BIOPHARMA INC
Sutro Biopharma, Inc. is a clinical stage drug discovery, development, and manufacturing company. It is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. It is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
Buy US stocks in Australia starting with STRO. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in STRO
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.